Epax®, leading supplier of high-purity, marine-derived, premium grade omega-3 fatty acid concentrates, will participate in the Vitafoods Europe trade exhibition at the Palexpo in Geneva, Switzerland, May 6 to 8, 2014. Epax is a member of the Vitafoods Europe Steering Committee, an event sponsor and will be exhibiting at stand #17037 with key executives from the company in attendance.
Epax will exhibit its premium-quality EPA/DHA Core and Ultra ranges of high concentrates in TGN, TG and EE formats. Epax has 175 years of experience producing quality ingredients for its B2B partners, and leading consumer brands globally rely on the Epax condition-specific omega-3 concentrates for their products.
Epax, a 10-year veteran of Vitafoods Europe, will take part in the Exhibitor Presentation Theatre at this year’s event. Jan Kopecky, MD, PhD from the Institute of Physiology at the Academy of Sciences of the Czech Republic will present on the “Effects of Omega-3 Fatty Acids on Metabolic Syndrome” on Tuesday, May 6th, 2014 at 14:35. The presentation will focus on research demonstrating the beneficial effects of marine omega-3 fatty acids on obesity and other related metabolic-syndrome abnormalities.
As emphasized by the Global Organization for EPA and DHA Omega-3 (GOED), building trust with consumers is paramount in driving growth in the category. Epax delivers high-quality ingredients based on its commitment to purity, quality, innovation and customer support. This enables brand owners to offer excellence, safety and transparency. Epax’s accurate product information and labelling arms end-consumers with the tools needed to make good, healthy choices based on purity and quality.
Epax continues to demonstrate its unwavering commitment, continued support and development of the consumer health marketplace with attractive, high-quality, safe nutraceutical ingredients. With ageing populations and increasing health problems, both in established and developing countries, Epax recognizes the growing market interest in the health benefits of omega-3 EPA/DHA supplementation. Increased developments in the pharmaceutical category, particularly very high concentrates, also provide additional growth opportunities extending into the nutraceutical segment. This enables brand owners to further differentiate their omega-3 concentrate products.
Epax remains committed to its watchwords – Purity, Quality and Innovation, and delivering on this platform is how it continues to contribute to building trustworthy brands in the marketplace. Epax continues to invest heavily in advancing technology and furthering environmental initiatives as part of the Purity, Quality, and Innovationcommitment. Over the last three years, Epax has invested $90 million USD in capacity and quality improvements, including opening a new processing plant in 2011 in Seal Sands, UK for ultra-high concentrates. The Epax processing plant at Seal Sands has been revamped and is now producing above expectations. The additional production capacity also further increases supply-chain security.